Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Frontage Holdings's average EBITDA Per Share Growth Rate was 35.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -7.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 6.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Frontage Holdings was 37.60% per year. The lowest was -7.40% per year. And the median was 19.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Frontage Holdings 3-Year EBITDA Growth Rate Related Terms
FGHQF vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Frontage Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Frontage Holdings 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Frontage Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Frontage Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -7.40% mean?
Frontage Holdings (FGHQF) has a 3-Year EBITDA Growth Rate of -7.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Frontage Holdings and its competitors. According to the industry distribution chart, Frontage Holdings ranks #869 out of 1122 companies in the Biotechnology industry, placing it in the top 77.5%.
Is Frontage Holdings' 3-Year EBITDA Growth Rate too high?
Frontage Holdings' current 3-Year EBITDA Growth Rate is -7.40%. Based on the distribution chart, Frontage Holdings ranks #869 out of 1122 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Frontage Holdings has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Frontage Holdings' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Frontage Holdings ranks #869 out of 1122 companies for 3-Year EBITDA Growth Rate. This places Frontage Holdings in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.75, based on 1,122 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Frontage Holdings and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Frontage Holdings's current 3-Year EBITDA Growth Rate is -7.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Frontage Holdings stock overvalued right now?
Based on GuruFocus' analysis, Frontage Holdings (FGHQF) is currently considered Fairly Valued. The stock's GF Value™ is $0.19, compared to a current price of $0.18 — trading 7.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -7.40%. Frontage Holdings' overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Frontage Holdings (FGHQF), the current 3-Year EBITDA Growth Rate is -7.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Frontage Holdings (FGHQF) Overvalued in 2026?
Based on GuruFocus' analysis, Frontage Holdings stock appears to be undervalued.
The current stock price of $0.18 is trading 7.9% below its estimated GF Value™ of $0.19.
GuruFocus considers Frontage Holdings to be Fairly Valued.
Key valuation signals for FGHQF:
3-Year EBITDA Growth Rate: -7.40%
GF Value™: $0.19 vs. price of $0.18 (7.9% below fair value)
No single metric tells the full story. See the FGHQF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Frontage Holdings Corp provides laboratory and related services to pharmaceutical and agrochemical companies. Its segments include North America and Europe segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the USA, Canada and Europe; and PRC segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the PRC. It derives majority of the revenue from North America and Europe segment. Geographically majority of the revenue is derived from USA and Canada.
67GF Score
Get the complete analysis for FGHQF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FGHQF has been successfully added to your 
